SEC Tracker
Get the app
ZEOX · XBRL financial data

Zeo ScientifiX financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ZEOX's year ends in late June)

In thousands of dollarsOct 31, 2023Jan 31, 2024Apr 30, 2024Aug 31, 2024Oct 31, 2024Jan 31, 2025Apr 30, 2025Jul 31, 2025Oct 31, 2025Jan 31, 2026Apr 30, 2026Jun 30, 2026
Revenue1,422*1,1541,131—1,244*1,0901,1491,3061,654*1,4462,581—
Cost of revenue133*159284—225*191256228256*281526—
Cost of goods and services sold————year only191256—year only281526—
Gross profit1,289*995847—1,019*8998931,0781,398*1,1652,055—
Research and development(15)*275—84*642—year only1931—
General and administrative2,521*2,1572,411—2,444*2,1522,2873,1492,066*2,0432,567—
Operating income (loss)(1,232)*(1,162)(1,564)—(1,425)*(1,253)(1,394)(2,071)(668)*(878)(512)—
Interest expense90*2720—22*22212332*1011—
Other income (expense)year only———year only—3—year only—(22)—
Net income (loss)(1,091)*(1,040)(1,399)—(1,254)*(1,243)(1,391)(2,072)(815)*(852)(145)—
Earnings per share, basic USD per share—(0.17)(0.23)—(0.19)*(0.20)(0.22)(0.32)(0.12)*(0.12)(0.02)—
Earnings per share, diluted USD per share—(0.17)(0.23)—(0.19)*(0.20)(0.22)(0.32)(0.12)*(0.12)(0.02)—
Weighted average shares, basic thousands of shares—6,1916,174—6,717*6,3456,3456,4056,543*7,0227,757—
Weighted average shares, diluted thousands of shares—6,1916,174—6,717*6,3456,3456,4056,543*7,0227,757—

Balance sheet

CSV

Fiscal quarters (ZEOX's year ends in late June)

In thousands of dollarsOct 31, 2023Jan 31, 2024Apr 30, 2024Aug 31, 2024Oct 31, 2024Jan 31, 2025Apr 30, 2025Jul 31, 2025Oct 31, 2025Jan 31, 2026Apr 30, 2026Jun 30, 2026
Cash and cash equivalents1,7561,172746—6577205423142211,0301,8462,265
Accounts receivable187760—194611—3563276245
Inventory310316272—232245235258423502686796
Total current assets2,2021,8921,418—1,1651,0908651,0639582,0073,2663,485
Property and equipment, net573533514—478460570589569564609595
Total assets2,7822,4321,932—1,6431,5501,4351,6521,5272,5713,8864,098
Current portion of long-term debt657663669—680686692698243245247248
Total current liabilities4,0103,9233,621—3,2883,3493,4533,8752,8732,8863,1113,420
Total liabilities4,0233,9403,632—3,2963,3553,5353,9662,9502,9543,1743,479
Accumulated deficit(57,508)(58,548)(59,947)—(62,213)(63,456)(64,847)(66,919)(67,734)(68,586)(68,731)(72,808)
Total stockholders' equity(1,241)(1,508)(1,700)—(1,653)(1,805)(2,100)(2,314)(1,423)(383)712583
Total liabilities and equity2,7822,4321,932—1,6431,5501,4351,6521,5272,5713,8864,098
Common shares outstanding (cover page) thousands of shares6,1256,1256,3326,5826,3456,3456,4506,5517,6157,7777,8377,837

Cash flows

CSV

Fiscal quarters (ZEOX's year ends in late June)

In thousands of dollarsOct 31, 2023Jan 31, 2024Apr 30, 2024Aug 31, 2024Oct 31, 2024Jan 31, 2025Apr 30, 2025Jul 31, 2025Oct 31, 2025Jan 31, 2026Apr 30, 2026Jun 30, 2026
Net income (loss)(1,091)*(1,040)(1,399)—(1,254)*(1,243)(1,391)(2,072)(815)*(852)(145)—
Stock-based compensation799*7731,187*—1,102*1,0911,0961,750*756*592590—
Depreciation and amortization16*1919*—18*1816*19*20*1919*—
Net cash from operating activities220*(575)(415)*—(366)*65(143)*(257)*(383)*(471)(138)*—
Purchases of property and equipment6*———————0*1464*—
Net cash from investing activities735*———0*———0*(14)312*—
Proceeds from issuing common stock0*———0*———year only1,300650*—
Net cash from financing activities167*(9)(11)*—(82)*(2)(35)*52*290*1,294642*—

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
  • A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Zeo ScientifiX2,265not reportednot reported7.8M— 10-KTJun 30, 2026
Sunshine Biopharma13,7489,264(918)*3.9M15.0 quarters 10-QJun 30, 2026
Neuphoria Therapeutics19,866year only1,214*5.4M— 10-KJun 30, 2026
CV Sciences2662,98520*225.8M— 10-QJun 30, 2026
Minerva Neurosciences24,652not reported(13,345)*47.7M5.6 quarters 10-QJun 30, 2026
Bolt Biotherapeutics12,8605(6,540)*1.9M2.7 quarters 10-QJun 30, 2026
Intensity Therapeutics9,529not reported(2,340)*3.3M4.1 quarters 10-QJun 30, 2026
Genprex15,154not reported(5,139)*819,7092.9 quarters 10-QJun 30, 2026
VivoSim Labs1,67018(3,213)14.9M0.5 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.